VERITAS: Harnessing the power of nomenclature in biologic discovery

References

• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. MAbs. 2022;14(1):2014296. doi:10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014. MAbs. 2014;6(1):5–9. doi:10.4161/mabs.27333.
   PubMed Web of Science ®Google Scholar
• Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G. Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions. Immunol Rev. 2016;270(1):193–208. PMID: 26864113. doi:10.1111/imr.12393.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:10.1016/j.ymeth.2018.10.026. PMID: 30395966.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallee F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs. 2016;8:867–78. PMID: 26984268. doi:10.1080/19420862.2016.1162932.
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90(14):6444–48. doi:10.1073/pnas.90.14.6444.
   PubMed Web of Science ®Google Scholar
• Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279(52):53907–14. PMID: 15471859. doi:10.1074/jbc.M407888200.
   PubMed Web of Science ®Google Scholar
• Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol. 2010;399(3):436–49. PMID: 20382161. doi:10.1016/j.jmb.2010.04.001.
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011;108(27):11187–92. PMID: 21690412. doi:10.1073/pnas.1019002108.
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol. 2007;25(11):1290–97. PMID: 17934452. doi:10.1038/nbt1345.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. PMID: 28071970. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem. 2010;285(25):19637–46. PMID: 20400508. doi:10.1074/jbc.M110.117382.
   PubMed Web of Science ®Google Scholar
• Ha JH, Kim JE, Kim YS. Immunoglobulin Fc Heterodimer platform technology: from design to applications in Therapeutic antibodies and proteins. Front Immunol. 2016;7:394. PMID: 27766096. doi:10.3389/fimmu.2016.00394.
   PubMed Web of Science ®Google Scholar
• Sweet-Jones J, Ahmad M, Martin ACR. Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw). MAbs. 2022;14(1):2101183. PMID: 35838549. doi:10.1080/19420862.2022.2101183.
   PubMed Web of Science ®Google Scholar
• Elshiaty M, Schindler H, Christopoulos P. Principles and current clinical landscape of multispecific antibodies against cancer. Int J Mol Sci. 2021;22(11):5632. PMID: 34073188. doi:10.3390/ijms22115632.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012;4(2):182–97. PMID: 22453100. doi:10.4161/mabs.4.2.19000.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47. PMID: 25728220. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. PMID: 31175342. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific antibodies: from research to clinical application. Front Immunol. 2021;12:626616. PMID: 34025638. doi:10.3389/fimmu.2021.626616.
   PubMed Web of Science ®Google Scholar
• Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):130. PMID: 26692321. doi:10.1186/s13045-015-0227-0.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67(2):95–106. PMID: 25637431. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen DT, Jacinto J, Eivazi A, Nisthal A, Diaz JE, Chu SY, et al. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods. 2019;154:38–50. PMID: 30366098. doi:10.1016/j.ymeth.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Kunz RK, Rojnuckarin A, Schmidt CM, Miranda LP. Development of human-machine language interfaces for the visual analysis of complex biologics and RNA modalities and associated experimental data. AAPS Open. 2023;9(1):9. doi:10.1186/s41120-023-00073-w.
   PubMedGoogle Scholar
• Suurs FV, Lub-de Hooge MN, de Vries EGE, de Groot DJA. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol Ther. 2019;201:103–19. PMID: 31028837. doi:10.1016/j.pharmthera.2019.04.006.
   PubMed Web of Science ®Google Scholar